Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms

Purpose Caveolin-1 (CAV-1) expression is more associated with basal-like cancers than estrogen receptor- or ErbB-2–expressing breast cancers. However, the biological relevance of different levels of CAV-1 expression according to subtype in the epithelial compartment of breast cancer remains unclear. Materials and Methods We investigated whether CAV-1 functions as a tumor suppressor and/or modulator of the cytotoxic activity of docetaxel (DTX) in subtypes of breast cancer using in vitro and xenograft models. Results The levels of CAV-1 expression were closely associated with DTX sensitivity in triple-negative breast cancer cells. In addition, CAV-1 significantly inhibited cell proliferation and modulated DTX-induced apoptosis through cell cycle arrest in the G2/M phase. The mechanisms underlying DTX-induced apoptosis differed in breast cancers according to the levels of CAV-1 expression. DTX robustly enhanced Bcl-2 inactivation by CAV-1 in MDA-MB-231 cells, while p53-mediated cell cycle arrest by DTX was more pronounced in CAV-1–low but p53-functional MCF-7 cells. In parallel with the data from breast cancer cell lines, CAV-1–transfected MCF-7 cells showed higher efficacy of DTX treatment in a xenograft model. Conclusion We clearly demonstrated cooperative effects between CAV-1 and DTX in mediating apoptosis, suggesting that the levels of CAV-1 expression might be an important indicator for DTX use in breast cancer.

[1]  F. Sotgia,et al.  Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery , 2013, Cell cycle.

[2]  F. Beca,et al.  Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: Key events in the progression from an in situ to an invasive breast carcinoma , 2013, Cell cycle.

[3]  Xuelei Ma,et al.  Prognostic role of caveolin in breast cancer: a meta-analysis. , 2013, Breast.

[4]  L. Lum,et al.  A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[5]  J W Gray,et al.  CpG island shore methylation regulates caveolin-1 expression in breast cancer , 2012, Oncogene.

[6]  V. Speirs,et al.  Clinical and functional significance of loss of caveolin‐1 expression in breast cancer‐associated fibroblasts , 2012, The Journal of pathology.

[7]  S. Dakshanamurthy,et al.  Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK)* , 2012, The Journal of Biological Chemistry.

[8]  R. Moorehead,et al.  Caveolin-1 expression is elevated in claudin-low mammary tumor cells , 2012, Cancer Cell International.

[9]  F. Sotgia,et al.  Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. , 2012, Annual review of pathology.

[10]  Yuan Qi,et al.  Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer , 2010, Clinical Cancer Research.

[11]  E. Álava,et al.  Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer , 2010, Breast Cancer Research and Treatment.

[12]  G. Hortobagyi,et al.  Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Goh,et al.  Correlation of RRM1 promoter region single nucleotide polymorphisms (SNPs) with response and outcome in breast cancer patients treated with gemcitabine-based chemotherapy , 2008 .

[14]  Y. Fujii,et al.  The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. , 2007, Oncology reports.

[15]  Robert Clarke,et al.  Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity* , 2007, Journal of Biological Chemistry.

[16]  Robin L. Jones,et al.  Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis , 2007, Clinical Cancer Research.

[17]  S. Merajver,et al.  Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer , 2006, Breast Cancer Research and Treatment.

[18]  S. Kim,et al.  Caveolin‐1 is down‐regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast , 2005, Histopathology.

[19]  John N. Hutchinson,et al.  Caveolin-1 Gene Disruption Promotes Mammary Tumorigenesis and Dramatically Enhances Lung Metastasis in Vivo , 2004, Journal of Biological Chemistry.

[20]  J. Gligorov,et al.  Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.

[21]  G. Fiucci,et al.  Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells* , 1998, The Journal of Biological Chemistry.

[22]  M. Lisanti,et al.  Upregulation of caveolin‐1 and caveolae organelles in Taxol‐resistant A549 cells , 1998, FEBS letters.

[23]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[24]  D. Baltimore,et al.  Reduction of caveolin and caveolae in oncogenically transformed cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Chih-Hsin Yang,et al.  Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. , 2008, Lung cancer.

[26]  K. Lyseng-Williamson,et al.  Docetaxel: a review of its use in metastatic breast cancer. , 2005, Drugs.